- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma
This study is testing an immunotherapy called LN-145 for women with cervical cancer that has come back, spread, or hasn't responded to other treatments. It's looking at how well the treatment shrinks tumours and if it's safe to use.
For: Recurrent · metastatic · or persistent Cervical CarcinomaGermany · Netherlands · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors
This study looks at a new treatment for solid tumours, which are common types of cancer. It uses a patient's own immune cells, called TILs, to fight the cancer. Researchers want to see how well these cells work at shrinking tumours and keeping the cancer away.
For: NeoplasmSpain · Germany · Greece - Recruiting
Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study
This study is checking on people who previously took part in the IVORY trial. It's looking at whether a low dose of a medicine called IL-2 helped reduce heart problems in people who had a heart attack, by lowering inflammation in their blood vessels.
For: Acute Coronary SyndromesUnited Kingdom - Active not recruitingPHASE2
Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)
This study is looking into a new medicine called aldesleukin for children and young adults with newly diagnosed Type 1 diabetes. We want to see if it can help their bodies keep making their own insulin for longer, which could improve their health and make managing diabetes easier.
For: Type1 DiabetesUnited Kingdom - AuthorisedTherapeutic exploratory (Phase II)
A phase 2, Multicenter Study of TILs Treatment in Germ Cell tumors: the ARES Study
This study is looking at a new treatment for certain types of advanced germ cell tumours that haven't responded to standard chemotherapy. It uses a type of immunotherapy where a patient's own immune cells are specially treated to fight the cancer, combined with other medicines.
For: Germ Cell Tumors refractory to salvage chemotherapySpain - AuthorisedPhase I and Phase II (Integrated)- Other
OVACURE-2: Adoptive T cell therapy plus low dose IL-2 (IL-2ld) as first line neoadjuvant therapy in patients with stage III/IV ovarian cancer
This study looks at a new treatment called adoptive T cell therapy, combined with a low dose of a medicine called IL-2, for women with advanced ovarian cancer. It's an early-stage study testing how safe this treatment is.
For: Ovarian carcinomaNetherlands - RecruitingPHASE3
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
This study looks at new ways to treat a serious childhood cancer called neuroblastoma. It tests different treatment combinations, including chemotherapy and immunotherapy, to find the best approach for children with high-risk forms of the disease. The aim is to improve their chances of getting better.
For: NeuroblastomaAustralia · Austria · Belgium